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Abstract 
Introduction: Current drug therapy of ophtalmic diseases associated with retinal ischemia is not always successful enough 
that ensures the relevance of the search of new effective drugs. 
Objective: Improving the pharmacological correction efficiency of the retinal ischemic damage in the experiment using 
non-selective imidazoline receptor agonists. 
Materials and methods: The retinal ischemia-reperfusion model in rats was used, in which an increase in intraocular 
pressure is carried out by mechanical pressure to the front chamber. The retinoprotective effects of the nonselective 
imidazoline receptor agonists: the sodium salt of C7070, the potassium salt of C7070 and C7070, treated with carbon 
dioxide, were estimated by the changes in the ratio of the amplitudes of the b- and a-waves of electroretinogramm – the b/a 
coefficient. Measuring the retinal microcirculation level was carried out using laser Doppler flowmetry. 
Results and Discussion: The most pronounced retinoprotective effect is demonstrated by potassium salt of C7070 in a 
dose of 10 mg/kg, which is expressed in reaching the target values of the b/a and the retinal microcirculation level. When 
the pathology is corrected with sodium salt of C7070 in a dose of 10 mg/kg, the microcirculation level increases by 70.4% 
(p < 0.05), b/a increased by 94% (p < 0.05) compared with the group without correction. With the correction of retinal 
ischemia by C7070, treated with CO2, in a dose of 10 mg/kg, the microcirculation level increased by 12% (p > 0.05), b/a 
increased by 84% (p < 0.05), compared with the group without correction. 
Conclusion: The obtained data give an experimental substantiation of the pharmacological correction possibility of retinal 
ischemia by imidazoline receptor agonists. 
Keywords: Imidazoline Receptor Ligands, C7070, Retinal Ischemia-Reperfusion Model, Rats. 
 
Introduction 
Retinal ischemia may have different etiology: 
central retinal artery (CRA) occlusion and occlusion 
of its branches, carotid arteries atherosclerosis, 
glaucoma with normal intraocular pressure (IOP), 
endocrine ophthalmopathy, surgical operation and so 
on. CRA occlusion is observed in 57% of cases, its 
branches occlusion – in 38%. Acute occlusion of 
retinal arteries in 91.2% of cases occurs against the 
background of the cardiovascular system diseases [1]. 
Local circulatory disorders in the retinal arterial 
system are observed in diabetic, hypertensive 
retinopathy (neuroretinopathy), optic nerve atrophy 
vascular origin, anterior ischemic optic neuropathy 
etc. [2, 3, 4, 5, 30]. 
Studying the way of how to improve retinal tissue 
tolerance to ischemia is an actual problem of modern 
pharmacology and ophthalmology. Up to now, the 
treatment of ischemic retinal conditions was done by 
use of angioprotectors, antioxidants, fibrinolytics, 
anticoagulants and others. As the authors note, due to 
the instability and short-term effects after using these 
drugs in combination with other drugs and 
physiotherapy treatments is necessary to seek out a 
more effective way to improve blood circulation and 
increase resistance to ischemic retinal tissue having a 
specific orientation [6, 7, 8, 31]. Thus, an important 
task is to find new, specific and highly effective 
means for correcting of retinal ischemia. 
Imidazoline receptors (IR) of type II are a new 
biological target for the treatment of neurological 
disorders [9]. IR of type II are widely distributed in 
the brain, and their ligands may have therapeutic 
potential as neuroprotectors [10]. 
IR of type III perform their function by regulating 
the concentration of K+ and Ca2+ in cells and is 
associated with the activation of ATP-dependent 
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potassium channels [11], which is expected to have a 
positive effect in the correction of ischemic 
conditions. 
To study the pharmacological activity of new 
biologically active substances [12], as well as study 
the new effects of already known drugs [13], it is 
necessary to conduct experimental studies in vitro and 
in vivo [14]. 
In view of the above, it is important to study the 
possibilities of pharmacological correction of retinal 
ischemia using non-selective imidazoline receptor 
agonists in the experiment. 
Objective of the study is improving the 
pharmacological correction efficiency of the retinal 
ischemic damage in the experiment using non-
selective imidazoline receptor agonists. 
Materials and Methods 
Experiments were carried out on 80 rats Wistar 
weighing 225-275 g. For the study, the rats were taken 
with no external signs of disease, having passed the 
quarantine regime. Ethical principles of handling 
laboratory animals were observed in accordance with 
the European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other 
Scientific Purposes, CETS No. 123. 
The following groups were included in the 
experiment: 
The first (n = 10) – an intact group;  
The second (n = 10) – a group with the simulated 
retinal ischemia; 
The third (n = 10) – a group with correction of the 
retinal ischemia by potassium salt of C7070 in a dose 
of 10 mg/kg;  
The fourth (n = 10) – a group with the correction 
by sodium salt of C7070 in a dose of 10 mg/kg; 
The fifth (n = 10) – a group with the correction by 
C7070, treated with CO2, in a dose of 10 mg/kg; 
The sixth (n = 10) – a group with the correction by 
potassium salt of C7070 in a dose of 10 mg/kg + 
glibenclamide in a dose of 5 mg/kg; 
The seventh (n = 10) – a group with the correction 
by sodium salt of C7070 in a dose of 10 mg/kg + 
glibenclamide in a dose of 5 mg/kg; 
The eighth (n = 10) – a group with the correction 
by C7070, treated with CO2, in a dose of 10 mg/kg + 
glibenclamide in a dose of 5 mg/kg. 
Retinal ischemic injury was simulated under 
general anesthesia (chloral hydrate, 300 mg/kg, 
intraperitoneally (i.p.) by applying mechanical 
pressure, 110 mm Hg, to the anterior eye chamber for 
30 min. Mechanical pressure was carried out by a 
metal rod with an atraumatic surface placed in the 
cylinder with piston system with a calibration scale 
[15]. 
Potassium salt of С7070 (the potassium salt of 3-
(1H-benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid) under laboratory code 
K+C7070 («JSC Experimental Plant VladMiVa», 
Belgorod, Russia) was injected intragastrically (i.g.) 
in a dose of 10 mg/kg as a single dose 60 min before 
the retinal ischemia simulation in a 1% starch 
solution. 
Sodium salt of С7070 (the sodium salt of 3-(1H-
benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid) under laboratory code 
Na+C7070 («JSC Experimental Plant VladMiVa», 
Belgorod, Russia) was injected i.g. in a dose of 10 
mg/kg as a single dose 60 min before the retinal 
ischemia simulation in a 1% starch solution. 
С7070 (3-(1H-benzimidazol-2-il)-1,2,2-trimethyl 
cyclopentancarbonic acid) [16], treated with CO2, 
under laboratory code С7070СО2 («JSC Experimental 
Plant VladMiVa», Belgorod, Russia) was injected i.g. 
in a dose of 10 mg/kg as a single dose 60 min before 
the retinal ischemia simulation in a 1% starch 
solution. 
Glibenclamide, ATP-dependent potassium 
channels blocker, was administered in a dose of 5 
mg/kg i.g. once 1 hour before retinal ischemia-
reperfusion modeling. 
Electroretinography (ERG) in rats was performed 
according to the method previously published by us. 
To perform ERG, rats were kept in the dark for 30 
min, then anesthetized (chloral hydrate, 300 mg/kg, 
i.p.). Evoked biopotentials were run at a frequency of 
1–1000 Hz, amplified, averaged, and presented 
graphically on the screen using the MP150 data 
acquisition and analysis system (Biopac Systems, Inc., 
CA, USA) [17]. The duration of the flashes was 0.025 
sec, intensity was 30 kV. ERG registration was carried 
out in response to a single stimulation. The ERG 
recording was carried out for 0.5 sec on each rat in the 
groups. To assess the degree of retinal ischemia, the 
ratio of the amplitudes of the b- and a-waves, the b/a 
coefficient was evaluated. The mean was derived for 
each group from ten values received and was 
introduced into the protocol [18]. 
Measuring the retinal microcirculation level in rats 
was carried out by laser Doppler flowmetry (LDF) 
[19]. Registration was carried out by MP150 data 
acquisition and analysis systems and the TSD144 
needle-type sensor, with AcqKnowledge 4.2 software 
(BIOPAC Systems, Inc., CA, USA). After animal 
anesthesia, assessment of microcirculation level was 
carried out at 10 points on the circumference of the 
eyeball; the recording duration of the microcirculation 
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level readings at one point was 20 sec. From the 
microcirculation level results at every point, the mean 
value was calculated, which was taken as the indicator 
of the microcirculation level in the retina of the 
experimental animal. The microcirculation value in 
the animal group was calculated as the mean of the 
values obtained from each experimental animal [20]. 
For all data, descriptive statistics were used, and 
the data were checked for normal distribution. 
Distribution type was determined by using the 
criterion of Shapiro-Wilk. In case of normal 
distribution, the average value (M) and standard error 
of the mean (m) were calculated. In cases of abnormal 
distribution, the median (Me) and the quartile range 
(QR) were calculated. Between-group differences 
were analyzed by parametric (t-Student criterion) or 
non-parametric (Mann-Whitney test) methods, 
depending on the type of distribution. Differences 
were determined at a 0.05 significance level. 
Statistical analyses were performed using Statistica 
10.0 software. 
Results 
Evaluation of Electrophysiological Retinal 
Condition. Microcirculatory and neuronal damage 
of the retina after 72 hours of reperfusion after a 
long ischemic episode led to electrophysiological 
changes, namely, to a significant decrease in the 
amplitude of the b-wave, with relative preservation 
of the a-wave amplitude (table 1). Changes in the 
b-wave are pronounced due to damage, mainly, 
neurons of the inner nuclear layer. 
 
Table-1: Influence of potassium salt of С7070, sodium salt of С7070 and C7070, treated with carbon 
dioxide, on the a- and b- waves amplitudes when correcting retinal ischemia-reperfusion (M ± m; n = 10), 
mV. 
Experimental Groups The a-Wave Amplitudes (n = 10) 
The b-Wave Amplitudes 
(n = 10) 
1. Intact 0.35 ± 0.03 0.88 ± 0.07 у 
2. Retinal ischemia-reperfusion model 0.37 ± 0.03 0.44 ± 0.03 * 
3. Ischemia-reperfusion + K+C7070, 10 mg/kg 0.35 ± 0.02 0.84 ± 0.03 у 
4. Ischemia-reperfusion + Na+C7070, 10 mg/kg 0.36 ± 0.02 0.83 ± 0.05у 
5. Ischemia-reperfusion + C7070CO2, 10 mg/kg 0.37 ± 0.03 0.81 ± 0.06у 
6. Ischemia-reperfusion + K+C7070, 10 mg/kg + 
glibenclamide, 5 mg/kg 0.35 ± 0.02 0.70 ± 0.06 
у 
7. Ischemia-reperfusion + Na+C7070, 10 mg/kg + 
glibenclamide, 5 mg/kg 0.36 ± 0.04 0.65 ± 0.06*
у 
8. Ischemia-reperfusion + C7070CO2, 10 mg/kg + 
glibenclamide, 5 mg/kg 0.37 ± 0.02 0.48 ± 0.04 * 
* p < 0.05 compared to the intact; уp < 0.05 compared to the retinal ischemia-reperfusion model. 
In each group, the b/a coefficient was calculated, the 
values of which are presented in table 2. 
Table-2: Influence of potassium salt of С7070, sodium salt of С7070 and C7070, treated with carbon 
dioxide, on the value of the b/a coefficient when correcting retinal ischemia-reperfusion (M ± m; n = 10), 
R.U. 
Experimental Groups Ratio b/a (n = 10) 
1. Intact 2.51 ± 0.07 
2. Retinal ischemia-reperfusion model 1.19 ± 0.05* 
3. Ischemia-reperfusion + K+C7070, 10 mg/kg 2.40 ± 0.11 у 
4. Ischemia-reperfusion + Na+C7070, 10 mg/kg 2.31 ± 0.06у 
5. Ischemia-reperfusion + C7070CO2, 10 mg/kg 2.19 ± 0.09 у 
6. Ischemia-reperfusion + K+C7070, 10 mg/kg + glibenclamide, 5 mg/kg 2.00 ± 0.12 *у 
7. Ischemia-reperfusion + Na+C7070, 10 mg/kg + glibenclamide, 5 mg/kg 1.81 ± 0.09*у 
8. Ischemia-reperfusion + C7070CO2, 10 mg/kg + glibenclamide, 5 mg/kg 1.30 ± 0.09* 
R.U. – relative units; * p < 0.05 compared to the intact; у p < 0.05 compared to the retinal ischemia-
reperfusion model. 
 
When modeling retinal ischemia after 72 hours of 
reperfusion, the b/a decreased by 53% (p < 0.05) 
compared with the group of intact animals. With the 
injection of K+C7070 in a dose of 10 mg/kg b/a 
significantly increased by more than 2 times 
compared with the group without correction (p < 
0.05). In the group with the injection of Na+C7070 in 
a dose of 10 mg/kg b/a increased by 94% compared 
with the mean value in the group without correction (p 
< 0.05). When administered to animals C7070CO2 in 
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a dose of 10 mg/kg b/a in the group increased by 84% 
(p < 0.05), which is also significantly different from 
the mean value in the group without correction. 
Introduction of glibenclamide in the groups with 
correction of pathology by K+C7070, Na+C7070 the 
b/a increased by 68% and 52%, respectively, in 
comparison with the group with the model of retinal 
ischemia-reperfusion, which indicates partial 
preservation of retino protective properties against the 
background of blockade of ATP-sensitive potassium 
channels. In the group with the introduction of 
glibenclamide on the background of C7070CO2 
correction in a dose of 10 mg/kg, an increase in the 
b/a was prevented in comparison with the group 
without correction. 
Evaluation of Retinal Microcirculation. After 72 
hours of reperfusion, the microcirculation level in 
the retina was recorded by LDF. The results of the 
LDF are presented in table 3. 
 
Table-3: Influence of potassium salt of С7070, sodium salt of С7070 and C7070, treated with carbon 
dioxide, on the level of retinal microcirculation (M ± m), perfusion units 
Experimental Groups 
Level of 
microcirculation, P.U. (n 
= 10) 
1. Intact 743.9 ± 5.0 
2. Retinal ischemia-reperfusion model 353.3 ± 11.7* 
3. Ischemia-reperfusion + K+C7070, 10 mg/kg 732.7 ±16.9 у 
4. Ischemia-reperfusion + Na+C7070, 10 mg/kg 602.1 ± 15.0 *у 
5. Ischemia-reperfusion + C7070CO2, 10 mg/kg 398.2 ± 11.6 *y 
6. Ischemia-reperfusion + K+C7070, 10 mg/kg + glibenclamide, 5 mg/kg 450.4 ±14.2 *у 
7. Ischemia-reperfusion + Na+C7070, 10 mg/kg + glibenclamide, 5 mg/kg 428.5 ± 13.3*у 
8. Ischemia-reperfusion + C7070CO2, 10 mg/kg + glibenclamide, 5 mg/kg 365.1 ± 10.3* 
P.U. – perfusion units; * p < 0.05 compared to the intact; у p < 0.05 compared to the retinal ischemia-
reperfusion model. 
 
In the group with retinal ischemia-reperfusion 
model, the level of retinal blood flow is reduced more 
than in 2 times (p < 0.05) in comparison with the 
mean value in the group of intact animals. When 
correcting ischemia-reperfusion by K+C7070 in a dose 
of 10 mg/kg, the level of retinal microcirculation 
increased more than 2 times (p < 0.05) compared with 
the group without correction and did not differ from 
the mean value of the norm, which suggested the 
restoration of microcirculation in the retina. When the 
pathology is corrected by Na+C7070 in a dose of 10 
mg/kg, the level of microcirculation increased by 
70.4% (p < 0.05) compared with the group without 
correction, but did not reach the target values. When 
correcting C7070CO2 in a dose of 10 mg/kg, the 
microcirculation level increased by 12% compared 
with the value in the group without correction and did 
not differ significantly from it. In the group with 
correction by K+C7070 in a dose of 10 mg/kg and 
administration of glibenclamide in a dose of 5 mg/kg, 
the blood flow level in the retina significantly differs 
from the normal values, but is 27.5% higher than in 
the group without correction (p < 0.05). In the group 
with correction by Na+C7070 in a dose of 10 mg/kg 
and administration of glibenclamide in a dose of 5 
mg/kg, the level of blood flow in the retina is also 
significantly different from the norm and 21.3% 
higher than in the group without correction (p < 0.05). 
The introduction of glibenclamide in the group with 
correction by C7070CO2 in a dose of 10 mg/kg was 
almost completely prevented the increase in the level 
of retinal blood flow in comparison with the model of 
pathology. 
Discussion 
Based on the fact that electrophysiological studies 
often have a decisive importance in the early and 
differential diagnosis of retinal disorders, to study the 
correction of functional changes in the retina, 
researcher must conduct a comprehensive analysis, 
including electroretinography and microcirculation 
research [20, 28, 29]. Analysis of the dynamics of 
retinal electrogenesis allows to evaluate the nature and 
topography of retinal disorders and to identify the 
most labile hypoxic retinal structure, as well as their 
reaction to the correction by the medications. 
Previous studies showed that 2-(2-benzofuranyl)-
2-imidazoline (2-BFI), an immidazoline receptor 
ligand, dose-dependently protects rodent brains from 
cerebral ischemia injury. However, the molecular 
mechanisms remain unclear. In this study, was found 
that 2-BFI transiently and reversibly inhibits NMDA, 
but not AMPA currents, in a dose-dependent manner 
in cultured rat cortical neurons. 2-BFI also transiently 
and reversibly blocked NMDA receptor-mediated 
calcium entry to cultured neurons and provided long-
term neuroprotection against NMDA toxicity in vitro. 
Collectively, these studies demonstrated a potential 
mechanism of 2-BFI-mediated neuroprotection and 
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indicated that 2-BFI is an excellent candidate for 
repositioning as a drug for stroke treatment [21, 27]. 
It is known that activation of IR of type II reduces 
the voltage-dependent activation of Ca2+ channels in 
neurons innervating the blood vessels [22]. 
As a result of a series of experiments on cell 
cultures of insulinoma RIN-5AH, it was shown that 
the insulin secretagogue function of pancreatic β-cells 
is increased by the action of imidazoline compounds 
even with selective blocking of I1R and I2R. This 
research has indicated the presence of another 
imidazoline-sensitive receptor and initiated the 
investigation of I3R. Since the addition of an activator 
of K+-ATP-dependent diazoxin channels prevents 
insulinolysis, it is considered that I3R performs its 
function through regulation of K+ and Ca2+ 
concentrations of Langerhans cells. Later, β-carboline 
Harmane was found as its selective agonist [23, 25, 
26]. 
In the future interesting is the study of the 
influence of the studied imidazoline receptor agonists 
on the eNOs expression [24] in retinal vessels. 
In connection with the foregoing, the proposed 
mechanism of neuroretinoprotection of IR-agonist of 
type II can be associated with the inhibition of Na+/H+ 
ion channels in the retinal neurons, the inhibition of 
NMDA receptors; type III – with the activation of 
ATP-sensitive potassium channels in blood vessels 
and retinal neurons. 
Conclusion 
Presumably, ATP-sensitive potassium channels 
make a great contribution to the realization of 
retinoprotective effects of the studied non-selective 
IR-agonists, since their blockade by glibenclamide 
leads to partial elimination of the positive dynamics of 
electrophysiological parameters of the retina (values 
of the amplitude of the b-wave and b/a) and partial 
elimination of the positive dynamics of blood flow in 
the retina during the correction of retinal ischemia-
reperfusion by the studied substances. 
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